Discovery of immunopotentiatory drugs: current and future strategies.
Rhodes
J
J
Department of Gene and Protein Therapeutics, Glaxo Smith Kline Research and Development, Medicines Research Centre, Stevenage, UK. John.R.Rhodes@gsk.com
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines / Q000627:therapeutic use; D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D001547:Benzaldehydes / Q000627:therapeutic use; D001565:Benzoates / Q000627:therapeutic use; D029721:Drosophila Proteins; D015195:Drug Design; D006801:Humans; D016882:ISCOMs; D000077271:Imiquimod; D008562:Membrane Glycoproteins / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000378:metabolism; D018417:Th1 Cells / Q000276:immunology; D051193:Toll-Like Receptors
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D001547:Benzaldehydes; D001565:Benzoates; D029721:Drosophila Proteins; D016882:ISCOMs; D008562:Membrane Glycoproteins; D011956:Receptors, Cell Surface; D051193:Toll-Like Receptors; C059629:tucaresol; D000077271:Imiquimod